AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas

AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas

Abstract Introduction Isocitrate dehydrogenase (IDH) mutations are disease-defining mutations in IDH-mutant astrocytomas and IDH-mutant and 1p/19q-codeleted oligodendrogliomas. In more than 80% of these tumors, point mutations in IDH type 1 (IDH1) lead to expression of the tumor-specific protein IDH...

Full description

Bibliographic Details
Main Authors: Lukas Bunse, Anne-Kathleen Rupp, Isabel Poschke, Theresa Bunse, Katharina Lindner, Antje Wick, Jens Blobner, Martin Misch, Ghazaleh Tabatabai, Martin Glas, Oliver Schnell, Jens Gempt, Monika Denk, Guido Reifenberger, Martin Bendszus, Patrick Wuchter, Joachim P Steinbach, Wolfgang Wick, Michael Platten
Format: Article
Language:English
Published: BMC 2022-05-01
Series:Neurological Research and Practice
Subjects:
Isocitrate dehydrogenase 1
Peptide vaccine
Astrocytoma
Oligodendroglioma
Recurrent glioma
Window-of-opportunity
Online Access:https://doi.org/10.1186/s42466-022-00184-x

Internet

https://doi.org/10.1186/s42466-022-00184-x

Similar Items